p15Ink4b: Dual function in myelopoiesis and inactivation in myeloid disease

Blood Cells, Molecules, and Diseases

Volumn 40, Issue 3, 2008, Pages 406-409

  Rosu Myles, Michael ^a   Wolff, Linda ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AML; Gene silencing; MDS; Myeloid progenitors; p15Ink4b

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; GENE SILENCING; HUMAN; MYELOID DYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPOIESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; G1 PHASE; HUMANS; LEUKEMIA, MYELOID; MYELOID CELLS; MYELOID PROGENITOR CELLS; MYELOPOIESIS;

EID: 41949106988     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2007.09.005     Document Type: Article

References (37)

1. Ortega S., Malumbres M., and Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602 (2002) 73-87
2. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
3. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
4. Pardee A.B. G1 events and regulation of cell proliferation. Science 246 (1989) 603-608
5. Wolff L., et al. Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-deficient mice. Oncogene 22 (2003) 9265-9274
6. Santamaria D., and Ortega S. Cyclins and CDKS in development and cancer: lessons from genetically modified mice. Front. Biosci. 11 (2006) 1164-1188
7. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia 12 (1998) 845-859
8. Wong I.H., Ng M.H., Huang D.P., and Lee J.C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95 (2000) 1942-1949
9. Teofili L., et al. Hypermethylation of GpG islands in the promoter region of p15(INK4b) in acute promyelocytic leukemia represses p15(INK4b) expression and correlates with poor prognosis. Leukemia 17 (2003) 919-924
10. Shimamoto T., Ohyashiki J.H., and Ohyashiki K. Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. Leuk. Res. 29 (2005) 653-659
11. Herman J.G., Jen J., Merlo A., and Baylin S.B. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56 (1996) 722-727
12. Guo S.X., et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk. Res. 24 (2000) 39-46
13. Cameron E.E., Baylin S.B., and Herman J.G. p15INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94 (1999) 2445-2451
14. Aggerholm A., Holm M.S., Guldberg P., Olesen L.H., and Hokland P. Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur. J. Haematol. 76 (2006) 23-32
15. Agrawal S., et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 67 (2007) 1370-1377
16. Uchida T., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90 (1997) 1403-1409
17. Tien H.F., et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br. J. Haematol. 112 (2001) 148-154
18. Teofili L., et al. Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood 98 (2001) 495-497
19. Quesnel B., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 (1998) 2985-2990
20. Markus J., et al. Methylation-independent silencing of the tumor suppressor INK4b (p15) by CBFbeta-SMMHC in acute myelogenous leukemia with inv(16). Cancer Res. 67 (2007) 992-1000
21. Schmidt M., Koller R., Haviernik P., Bies J., Maciag K., and Wolff L. Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation. Oncogene 20 (2001) 6205-6214
22. Schmidt M., Bies J., Tamura T., Ozato K., and Wolff L. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood 103 (2004) 4142-4149
23. Amanullah A., Hoffman B., and Liebermann D.A. Deregulated E2F-1 blocks terminal differentiation and loss of leukemogenicity of M1 myeloblastic leukemia cells without abrogating induction of p15(INK4B) and p16(INK4A). Blood 96 (2000) 475-482
24. Teofili L., et al. Expression of cyclin-dependent kinase inhibitor p15INK4B during normal and leukemic myeloid differentiation. Exp. Hematol. 28 (2000) 519-526
25. Teofili L., et al. Expression of p15INK4B in normal hematopoiesis. Exp. Hematol. 26 (1998) 1133-1139
26. Guo Y., Engelhardt M., Wider D., Abdelkarim M., and Lubbert M. Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells. Leukemia 20 (2006) 115-121
27. Furukawa Y., Kikuchi J., Nakamura M., Iwase S., Yamada H., and Matsuda M. Lineage-specific regulation of cell cycle control gene expression during haematopoietic cell differentiation. Br. J. Haematol. 110 (2000) 663-673
28. Bergh G., Ehinger M., Olsson I., Jacobsen S.E., and Gullberg U. Involvement of the retinoblastoma protein in monocytic and neutrophilic lineage commitment of human bone marrow progenitor cells. Blood 94 (1999) 1971-1978
29. Haviernik P., Schmidt M., Hu X., and Wolff L. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc. Oncogene 22 (2003) 1600-1610
30. Rosu-Myles M., Taylor B.J., and Wolff L. Loss of the tumor suppressor p15Ink4b enhances myeloid progenitor formation from common myeloid progenitors. Exp. Hematol. 35 (2007) 394-406
31. Latres E., et al. Limited overlapping roles of P15INK4b and P18INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J. 19 (2000) 3496-3506
32. Raj K., et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 21 (2007) 1937-1944
33. Takanashi M., Motoji T., Oshimi K., and Mizoguchi H. Effect of recombinant interferons on colony formation of blast progenitors in acute myeloblastic leukemia. Exp. Hematol. 15 (1987) 946-951
34. Rigby W.F., Ball E.D., Guyre P.M., and Fanger M.W. The effects of recombinant-DNA-derived interferons on the growth of myeloid progenitor cells. Blood 65 (1985) 858-861
35. Benjamin R., et al. Continuous delivery of human type I interferons (alpha/beta) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model. Blood 109 (2007) 244-1247
36. Wolff L., et al. A novel retrovirus provides the cooperating oncogenic event(s) required to demonstrate the tumor suppressor activity of p15Ink4b in myeloid cells in vivo. Blood Cells Mol. Diseases 32 (2004) 226-231
37. Wolff L., Koller R., Hu X., and Anver M.R. A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms. J. Virol. 77 (2003) 4965-4971